MXPA04004844A - Tratamiento de hipertonia durante la fase aguda de un accidente cerebrobascular. - Google Patents

Tratamiento de hipertonia durante la fase aguda de un accidente cerebrobascular.

Info

Publication number
MXPA04004844A
MXPA04004844A MXPA04004844A MXPA04004844A MXPA04004844A MX PA04004844 A MXPA04004844 A MX PA04004844A MX PA04004844 A MXPA04004844 A MX PA04004844A MX PA04004844 A MXPA04004844 A MX PA04004844A MX PA04004844 A MXPA04004844 A MX PA04004844A
Authority
MX
Mexico
Prior art keywords
cerebrovascular accident
acute phase
treatment during
hypertonia
hypertonia treatment
Prior art date
Application number
MXPA04004844A
Other languages
English (en)
Inventor
Schrader Joachim
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of MXPA04004844A publication Critical patent/MXPA04004844A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a el uso de una sustancia para inhibir el sistema renina-angiotensina durante el tratamiento de accidente cerebrovascular agudo.
MXPA04004844A 2001-11-23 2002-11-25 Tratamiento de hipertonia durante la fase aguda de un accidente cerebrobascular. MXPA04004844A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10157474 2001-11-23
DE10158030 2001-11-27
PCT/EP2002/013238 WO2003043615A2 (de) 2001-11-23 2002-11-25 Hypertoniebehandlung während der akuten phase des schlaganfalls

Publications (1)

Publication Number Publication Date
MXPA04004844A true MXPA04004844A (es) 2004-07-30

Family

ID=26010631

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004844A MXPA04004844A (es) 2001-11-23 2002-11-25 Tratamiento de hipertonia durante la fase aguda de un accidente cerebrobascular.

Country Status (9)

Country Link
US (1) US20050009893A1 (es)
EP (1) EP1450793A2 (es)
JP (1) JP2005511631A (es)
AU (1) AU2002364381A1 (es)
BR (1) BR0214383A (es)
CA (1) CA2467095A1 (es)
MX (1) MXPA04004844A (es)
PL (1) PL370270A1 (es)
WO (1) WO2003043615A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
DE60022525T2 (de) * 1999-08-30 2006-06-14 Sanofi Aventis Deutschland Ramipril zur vorbeugung von kardiovaskulären vorfällen
US8763642B2 (en) 2010-08-20 2014-07-01 Integenx Inc. Microfluidic devices with mechanically-sealed diaphragm valves
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
US9333233B2 (en) * 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
CA2048699A1 (en) * 1990-09-04 1992-03-05 Abraham Sudilovsky Method for preventing or treating cerebro-vascular disease employing ceronapril
US20010018448A1 (en) * 1990-12-14 2001-08-30 Smithkline Beecham P.L.C. Medicament
GB9027199D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
UA49880C2 (uk) * 1996-03-29 2002-10-15 Смітклайн Бічам Корпорейшн Дигідрат ерпоcартану, фармацевтична композиція, спосіб отримання твердої дозованої форми, спосіб блокування рецепторів ангіотензину іі
PL197164B1 (pl) * 1997-10-17 2008-03-31 Ark Therapeutics Ltd Zastosowanie inhibitorów układu renina-angiotensyna
JP4588877B2 (ja) * 1998-06-17 2010-12-01 ブリストル−マイヤーズ スクイブ カンパニー Ａｄｐ−受容体抗血小板物質と抗高血圧薬の組合せ投与による脳梗塞の予防
FR2783422A1 (fr) * 1998-09-21 2000-03-24 Sanofi Sa Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
CA2379666C (en) * 1999-07-21 2009-10-13 Takeda Chemical Industries, Ltd. Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
DE60022525T2 (de) * 1999-08-30 2006-06-14 Sanofi Aventis Deutschland Ramipril zur vorbeugung von kardiovaskulären vorfällen
WO2001072335A2 (en) * 2000-03-28 2001-10-04 Queen's University At Kingston Methods for effecting neuroprotection using a potassium channel modulator
RU2298418C2 (ru) * 2000-04-12 2007-05-10 Новартис Аг Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза)
WO2002049645A1 (en) * 2000-12-18 2002-06-27 Novartis Ag Therapeutic combination of amlodipine and benazepril
DE10115668A1 (de) * 2001-03-29 2002-10-10 Max Delbrueck Centrum Mittel zur Behandlung des Schlaganfalls

Also Published As

Publication number Publication date
WO2003043615A3 (de) 2004-02-19
BR0214383A (pt) 2004-11-03
PL370270A1 (en) 2005-05-16
JP2005511631A (ja) 2005-04-28
WO2003043615A2 (de) 2003-05-30
EP1450793A2 (de) 2004-09-01
CA2467095A1 (en) 2003-05-30
US20050009893A1 (en) 2005-01-13
AU2002364381A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
SG96222A1 (en) Device for treating a disc-shaped object
ZA200202461B (en) Compounds for the treatment of ischemia.
EP0760658A4 (en) COMPOUNDS INHIBITOR OF OSTEOCLASTE INDUCED BONE RESORPTION
HK1103928A1 (en) 2-oxy-4h-3,1-benzoxazin-4-ones for treatment of obesity
DE60016794D1 (de) Intraspinale botulinus-toxin-enthaltende verbindungen zur schmerzbehandlung
EP1496878A4 (en) TECHNIQUES FOR IDENTIFYING ANGIOGENESIS MODULATORS, COMPOUNDS DISCOVERED BY THESE TECHNIQUES AND TREATMENT TECHNIQUES USING THESE COMPOUNDS
ZA200205478B (en) Automatically operable safety shield system for syringes.
HK1051499A1 (en) Method for treating ocular pain
ZA9811507B (en) Combination effective for the treatment of impotence.
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
MXPA03008205A (es) Procedimiento para la preparacion de compuestos de imidazol.
MXPA04004844A (es) Tratamiento de hipertonia durante la fase aguda de un accidente cerebrobascular.
NZ308516A (en) Transdermal therapeutic system (tts) for administering testosterone
MXPA04003544A (es) Benzotriazepinas como ligandos del receptor de gastrina y colecistocinina.
AP2001002248A0 (en) Method for treating COPD.
PT1400522E (pt) Compostos para tratar a impotência
GB0019296D0 (en) Treatment for part processed leather
AU2002231777A1 (en) Use of mglur5 antagonists for the treatment of pruritic conditions
WO2001047505A3 (de) Verwendung von azolen zur prävention von hautkrebs
GB9918301D0 (en) Sewage processing treatment invention
MXPA03004454A (es) Derivados de imidazolona para el tratamiento de enfermedades virales.
WO2004006943A3 (fr) Utilisation d'un extrait de chrysanthellum
GB0125266D0 (en) Wastewater treatment system
DE60032621D1 (de) Die verwendung von estrogen-verbindungen zur behandlung von osteoporose
TR199902914T2 (xx) �zole sistolik hipertansiyonu tedavi y�ntemi.